Business Wire

THALES

23.1.2024 09:01:30 CET | Business Wire | Press release

Share
Thales and Quantinuum Launch Starter Kit to help Enterprises prepare for Post-Quantum Cryptography Changes Ahead

Thales, the leading global technology and security provider, today announced the launch of its PQC Starter Kit in collaboration with Quantinuum (https://www.quantinuum.com). This first-of-its-kind offering helps enterprises prepare for Post-Quantum Cryptography (PQC). The kit provides a trusted environment for businesses to test quantum-hardened PQC-ready encryption keys and understand the implications that quantum computing will have on the security of their infrastructure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123494135/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

While 73% of organizations recognize quantum computing poses a threat to traditional cryptography, 61% have yet to define a strategy for a post-quantum world1. Post Quantum Cryptography helps mitigate this threat. As a result, organizations around the world must test their ecosystem applications, data, and devices currently relying upon traditional cryptography to ensure minimal disruption when quantum-safe protocols become mandatory.

Todd Moore, Global Head of Data Security Products at Thales commented: “Thales is excited to offer a new solution to its customers to help them prepare for the implementation of Post-Quantum Cryptography. We understand the enormous challenges and complexities behind this upcoming disruption in cryptography and want to support customers as they transition to these new algorithms.. For organizations unsure of navigating this transition, we highly recommend testing current applications, data, and devices that use cryptographic protection as soon as possible to ensure a smooth shift to PQC. Although quantum computing may seem like a future-looking risk, with hackers using Harvest Now, Decrypt Later tactics, post-quantum resilience should be on every organization’s radar today.”

"Hardening encryption keys is critical for the post-quantum era, and Quantum Origin is a unique technology that provides verifiable quantum randomness to maximize encryption key strength. The combination of Quantum Origin and the Thales HSM is a strong solution for IT teams to help them with their PQC transition. We look forward to working with Thales to help smooth the shift to PQC,” added Duncan Jones, Head of Cybersecurity at Quantinuum.

The PQC Starter Kit will allow organizations to test within a trusted lab environment. Using the current NIST proposed algorithms that are built into the system, customers can test various security use cases including PKI, code-signing, TLS, and IoT, and observe the impact of implementing PQC technology in these simulated test-lab scenarios, all without impacting operational processes in real-world production environments. Organizations will also be able to identify potential weaknesses in their encryption deployment and apply changes to their IT infrastructure to protect themselves.

The first available PQC Starter Kit option incorporates Luna HSMs and Quantinuum’s quantum random number generation (QRNG) technology through which customers can ensure their keys are securely generated and stored while testing the PQC algorithms. The kit offers a choice of Luna HSMs (i.e. appliance or PCIe card) and Quantinuum’s Quantum Origin - the world’s only source of verified quantum entropy. A PQC Starter Kit for network encryption using Thales High Speed Encryptors (HSE) will be available next.

Learn more about the PQC Starter Kit in the customer case study here.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.

PLEASE VISIT
Thales Group
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group

1 Cybersecurity Weaknesses in Data in Motion - White Paper (thalesgroup.com)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240123494135/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye